Biotechnology

Wednesday Apr 10, 2024 - 9:29 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discusses Medicare Reimbursement Approval for CARE Oral Medical Devices in Proactive Interview

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is spotlighted in a recent Proactive interview. During the interview, Vivos CEO Kirk Huntsman and Proactive host Steve Darling discuss the latest news from the company, which is the regulatory approval for Medicare reimbursement of oral medical devices designed for…

Wednesday Apr 10, 2024 - 9:15 am

InvestorNewsBreaks – Telo Genomics Corp. (TSX.V: TELO) (OTCQB: TDSGF) Notes Key Milestone with Award of College of American Pathologists Accreditation

Telo Genomics (TSX.V: TELO) (OTCQB: TDSGF),a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, has received accreditation for its Toronto-based laboratory at the MaRS Center from the Accreditation Committee of the College of American Pathologists (“CAP”). The accreditation followed more than a year of preparation and an on-site inspection by the CAP Accreditation Programs.…

Tuesday Apr 09, 2024 - 12:35 pm

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Adds AI Expert to Support Development of Phase 2 Clinical Trial

IGC Pharma (NYSE American: IGC), a company focused on developing innovative solutions to address Alzheimer’s disease, has announced the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world’s top researchers. Dr. Arbelaez will support the development of the Phase 2 clinical trial of IGC Pharma’s lead therapeutic candidate IGC-AD1, targeting agitation in Alzheimer’s. “We welcome Dr. Pablo Arbelaez…

Tuesday Apr 09, 2024 - 11:04 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Achieves Milestone with CARE Oral Medical Devices Gaining Approval for Medicare Reimbursement

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, has obtained all required regulatory approvals so that its CARE oral medical devices can be reimbursed by Medicare. Calling this a “milestone achievement,” the company noted that millions of Medicare beneficiaries can now use and be reimbursed for allowable charges…

Tuesday Apr 09, 2024 - 9:42 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Releases Pricing for Mulitmillion-Dollar Public Offering

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has announced the pricing of its public offering. The offering is comprised of 2,234,043 shares of the company’s Class A common stock (or prefunded warrants) and warrants to purchase up to 2,234,043 shares of Class A common…

Monday Apr 08, 2024 - 11:07 am

InvestorNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Approved as US Government Vendor, Proprietary TRACER 1000 Listed on GSA

Astrotech (NASDAQ: ASTC), an innovative science and technology company, and its wholly owned subsidiary, 1st Detect Corporation, have announced that its TRACER 1000(TM) is now listed in the U.S. General Services Administration (“GSA”) IT Schedule 70, making the company an approved U.S. government vendor. The device can be found under Contract No. GS-35F-250GA with SRI Group LLC, Special Item Number 334290. According to the announcement, IT Schedule 70…

Friday Apr 05, 2024 - 11:59 am

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Developing Robust Product Lineup to Address ASD, Associated Neurodevelopmental Conditions

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company is on a promising path to address the unmet medical needs of ASD, bringing hope to millions. “ASD is a developmental disorder affecting how individuals interact with other people, behavior,…

Tuesday Apr 02, 2024 - 11:31 am

InvestorNewsBreaks – Astiva Health Setting New Standard for Patient-Centric Care

Astiva Health, a leading provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, is championing a model of care that emphasizes proactive health management and a healthy lifestyle over traditional reactive methods. “At the core of Astiva Health’s innovative approach is the principle of patient-centric care. This method prioritizes the active involvement of patients in their healthcare decisions, ensuring their preferences,…

Tuesday Apr 02, 2024 - 11:17 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Enters Acquisition Agreement to Acquire Biodefense Vaccine Developer

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF). Appili is a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. According to the agreement, Adivir Inc., a wholly owned subsidiary of Aditxt, will acquire all issued and outstanding Class A common shares…

Monday Apr 01, 2024 - 11:50 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in Upcoming Investor Events

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in two April investor conferences, including the MedInvest Biotech & Pharma Investor Conference and the 14th annual LD Micro Invitational. CNS Pharmaceuticals CEO John Climaco will present at the one-day MedInvest Biotech & Pharma Investor event,…

Monday Apr 01, 2024 - 10:18 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY 2023 Financial Report, Operational Update

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is reporting financial results and operating highlights for Q4 and full year 2023, for the period ended Dec. 31, 2023. The report noted that revenue came in at $3.2 million for Q4 2023 and $13.8 million for the full year;…

Monday Apr 01, 2024 - 10:01 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Year-End 2023 Financial Report, Business Update

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial-intelligence (“AI”) and machine-learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, is reporting on its financial and operating results for the year ended Dec. 31, 2023; the company also released a corporate update. The report noted POAI experienced a net loss of…

Wednesday Mar 27, 2024 - 1:50 pm

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Making Drugs Perform Better

Sigyn Therapeutics (OTCQB: SIGY), a medical technology company, is developing blood purification technologies to treat life-threatening conditions that are not addressed with current market-cleared drug agents as well as an expansive pipeline of technologies to optimize the benefit of cancer therapies. “The company’s lead product candidate, Sigyn Therapy(TM), is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal…

Wednesday Mar 27, 2024 - 9:12 am

InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Enters into $3M SPA with Leading Asset Management Company

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has received a $3 million strategic investment from funds managed by Bradbury Asset Management (Hong Kong) Limited, a leading asset management company. According to the announcement, IGC Pharma entered into a share purchase agreement (“SPA”) with Bradbury comprised of IGC issuing 8,823,529 shares of unregistered common stock that are not immediately tradable. The company anticipates using the…

Thursday Mar 21, 2024 - 3:32 pm

InvestorNewsBreaks – Astiva Health Is Reshaping Healthcare Delivery

Astiva Health CEO Dr. Tri Nguyen was the featured guest in a recent Bell2Bell Podcast episode. “During the podcast, Nguyen provided an in-depth look at how Astiva Health is reshaping healthcare delivery, including an overview of the company’s commitment to patient involvement in healthcare and highlights of the company’s innovative strategies in offering comprehensive care… ‘So Astiva, other than providing full medical-care prescription drugs, we…

Thursday Mar 21, 2024 - 9:54 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Receives Notification from NASDAQ of 180-Day Extension

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has been granted an additional 180 days to comply with NASDAQ’s minimum bid price requirement for the continued listing on the NASDAQ Capital Market. InMed received a letter from the exchange notifying it of the extended deadline, which will now be Sept. 16, 2024. According to…

Thursday Mar 21, 2024 - 9:18 am

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Financial Results, Corporate Highlights for Q4, FY 2023

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced its financial numbers and operational highlights for the fourth quarter and full year ended Dec. 31, 2023. According to the report, key achievements during the period included enrolling the first patients for a pivotal trial studying AIMIGo(TM) System for synthesizing a 12-lead ECG as well…

Wednesday Mar 20, 2024 - 1:31 pm

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”), is focusing its lead program on autism spectrum disorder (“ASD”), for which there is no approved pharmacologic treatment targeting cause and symptoms. “The current ASD treatments only address the symptoms of the condition but do not target the pathophysiology itself. PaxMedica is on a promising path to address the…

Wednesday Mar 20, 2024 - 12:17 pm

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Developing Innovative Technologies to Address Critical Healthcare Challenges

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, recently expanded its therapeutic candidates, introducing ImmunePrep(TM) to improve the delivery of immunotherapeutic antibodies to treat cancer. “The company is also developing ChemoPrep(TM) and ChemoPure(TM) to optimize chemotherapy delivery and reduce treatment toxicity. The company further disclosed that clinical site locations for first-in-human studies for Sigyn Therapy(TM) have been identified. Sigyn Therapy(TM) is a novel blood…

Wednesday Mar 20, 2024 - 9:45 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Releases Info on $6.5M Registered Direct Offering

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into definitive agreements. The agreements are for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) of the company and warrants to purchase up to 1,542,112 shares of common stock; the stocks and warrants are offered at…

Wednesday Mar 20, 2024 - 9:28 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Board Approves 1-for-10 Reverse Stock Split

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has announced a 1-for-10 reverse split of the company’s Class A common stock. The move was approved by the company’s board of directors during a special stockholder meeting. According to the announcement, the reverse split will become effective at 11:59 p.m. ET on March 26, 2024. Following that, the company’s Class…

Tuesday Mar 19, 2024 - 12:00 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company today announced its entry into definitive agreements for the sale and issuance of 1,542,112 shares of its common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 1,542,112 shares of common stock at a combined offering price of $4.215…

Tuesday Mar 19, 2024 - 11:31 am

InvestorNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) Work in Nanotechnology Highlighted in ‘First in Human’ Podcast

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, was featured in a recent episode of First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials. Hosted by Vial EVP Rich McCormick, the podcast is available for on-demand listening on First in Human by Vial. Rob Etherington, president, director and CEO of Clene joined…

Friday Mar 15, 2024 - 1:53 pm

InvestorNewsBreaks – Astiva Health Addressing Challenges of Traditional Caregiving Structures

Astiva Health is a leading healthcare provider that specializes in delivering personalized and comprehensive solutions to diverse communities. The company is leading the charge in creating essential healthcare solutions tailored for the expanding aging Asian American community, which is undergoing a considerable demographic shift, with a growing segment of the population requiring more support. “The company is proactively meeting the unique needs of this group…

Friday Mar 15, 2024 - 1:11 pm

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Filling Gap in Therapeutic Antibody Treatment Space

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, is currently focused on the development of four therapeutic candidates to address clearly defined limitations in global health. These include the ImmunePrep(TM) platform to enhance the performance of immunotherapeutic antibodies to treat cancer, ChemoPrep(TM) to enhance the targeted delivery of chemotherapy, ChemoPure(TM) to reduce the toxicity of chemotherapy, and Sigyn Therapy(TM) to address pathogen-associated conditions that…

Friday Mar 15, 2024 - 10:34 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Publication of Peer-Reviewed Research for Investigational Drug CNM-Au8(R)

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced the publication of peer-reviewed research, titled “Protein Corona Composition of Gold Nanocrystals.” The publication appeared in the journal ACS Pharmacology & Translational Science and fully characterized the proteins from human…

Friday Mar 15, 2024 - 9:35 am

InvestorNewsBreaks – Cognition Therapeutics Inc. (NASDAQ: CGTX) Closes on $11.5M Public Offering

Cognition Therapeutics (NASDAQ: CGTX), a clinical-stage company developing product candidates designed to treat neurodegenerative disorders, has closed on its previously announced underwritten public offering. The offering was comprised of 6,571,428 shares of its common stock. According to the announcement, each share of common stock was sold at $1.75 per share, resulting in approximately $11.5 million in gross proceeds before deductions, commissions and expenses. Cognition Therapeutics…

Thursday Mar 14, 2024 - 2:31 pm

InvestorNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT) Announces Highly Promising Results from ODF Cladribine PK Study

BioNxt (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT) has announced completion of the comparative pharmacokinetic (“PK”) study for its oral dissolvable film (“ODF”) based proprietary Cladribine product for the treatment of multiple sclerosis (“MS”). The company reported that the animal PK study results are highly promising and demonstrated comparable rapid absorption and systemic exposure between BioNxt’s ODF product and the name-brand reference drug in all samples.…

Thursday Mar 14, 2024 - 12:00 pm

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Enrolls First Patients in Key Study Assessing Proprietary AIMIGo(TM) System

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has begun enrolling the first patients in its VALID-ECG pivotal study. According to the announcement, the first patients were enrolled at Atlanta Heart Specialists, a top cardiology physician practice in Atlanta, Georgia. HeartBeam anticipates the VALID-ECG study will form the basis of its planned FDA 510(k) submission.…

Wednesday Mar 13, 2024 - 11:54 am

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Shares Vision, Innovations in ASD Treatments in Updated Company Presentation

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. The comprehensive overview showcases PaxMedica’s strategic direction, recent advancements in autism spectrum disorder (“ASD”) therapeutics, and its commitment to addressing unmet needs within the ASD community. “PaxMedica is pleased to share our vision and progress with the wider community,” said Howard Weisman, chairman…

Wednesday Mar 13, 2024 - 11:37 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces FY 2023 Results, Recent Operating Highlights

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced its full year 2023 financial results. In addition, the company provided recent operating highlights for the clinical programs in amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “In 2024 we…

Tuesday Mar 12, 2024 - 12:47 pm

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Showcasing Services, Meeting with Investors at Upcoming BIO-Europe Spring 2024

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing CDMO services through its Scinai Bioservices business unit, will be participating at this month’s BIO-Europe Spring 2024 conference. The conference is scheduled for March 18–20, 2024, in Barcelona. According to the announcement, Scinai management will be attending the event and will be available for discussions with…

Monday Mar 11, 2024 - 10:43 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Takes First Step Toward Obtaining Permission for unbuzzd(TM) Phase-1b Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a Clinical Trial Application (“CTA”) for its planned phase-1b clinical trial. According to the announcement, the trial will focus on evaluating the safety and efficacy of unbuzzd(TM) in healthy volunteers in an induced state of…

Friday Mar 08, 2024 - 2:33 pm

InvestorNewsBreaks – Astrotech Corporation’s (NASDAQ: ASTC) Subsidiary Tapping into Fast-Growing Opportunity

Astrotech (NASDAQ: ASTC), a science and technology company focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries, recently released financial results for Q2 2024. “The company recorded a 512% jump in its year-to-date (‘YTD’) revenue to $1,540,000 from $301,000 in the comparative period a year before. Astrotech attributed this growth primarily to two significant purchase orders for the TRACER 1000(TM)…

Friday Mar 08, 2024 - 1:03 pm

InvestorNewsBreaks – Astiva Health Redefining Personalized and Comprehensive Healthcare Standards

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, is carving out a niche as a rapidly growing Medicare Advantage Prescription Drug (“MAPD”) health plan in a landscape where more individuals are becoming eligible for Medicare. “Astiva stands out by redefining personalized and comprehensive healthcare standards… Astiva is redefining healthcare standards by improving member services, medical…

Thursday Mar 07, 2024 - 12:17 pm

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Awarded Two New US Patents Covering Core Cardiac Monitoring Technology

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has received notification that two of its patents covering core vectorelectrocardiography (“VECG”) have been awarded by the United States Patent and Trademark Office. The two new patents bring the total of issued patents in HeartBeam’s portfolio to 14, with four international patents as well; the company also…

Thursday Mar 07, 2024 - 9:51 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming 36th Annual Roth Conference

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., will be represented at this month’s annual Roth Conference. The conference will be held March 18–19, 2024, in Dana Point, California. According to the announcement, company officials are scheduled to present a fireside chat, slated to begin at 8 a.m. PST on March 18, 2024. Clene focuses on improving…

Tuesday Mar 05, 2024 - 11:03 am

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q4 and FY 2023 Results Call

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced that it will hold a conference call to discuss its results for the fourth quarter and full fiscal year ended Dec. 31, 2023. During the call, slated to begin at 4:30 p.m. ET on Wednesday, March 20, 2024, HeartBeam executives will also provide regulatory updates,…

Tuesday Mar 05, 2024 - 10:49 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Presents Positive Results on First-in-Human Phase 1 Study of Lucid-MS

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced its participation in Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) 2024 Forum. Held during Feb. 29 - Mar 2, 2024, in West Palm Beach, Florida, the annual conference is the largest MS event of its kind in North…

Monday Mar 04, 2024 - 1:35 pm

InvestorNewsBreaks – BioVie Inc. (NASDAQ: BIVI) to Secure ~$21M in Public Offering

BioVie (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders. The company today announced the pricing of its best efforts public offering of 21,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 10,500,000 shares of common stock at a combined offering price…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions